Sugi Predict

Sugi Predict / Compounds / SCHEMBL407919

SCHEMBL407919

SCHEMBL407919

COc1cc(B2OC(C)(C)C(C)(C)O2)cnc1OC

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALPL P05186 1/20 0.46
▸ AAK1 Q2M2I8 1/20 0.42
▸ DGAT1 O75907 2/20 0.38
▸ LPL P06858 2/20 0.37
▸ LIPG Q9Y5X9 2/20 0.37
▸ CSF1R P07333 1/20 0.36
▸ EGFR P00533 1/20 0.35
▸ SNCA P37840 1/20 0.35
▸ GSK3A P49840 1/20 0.35
▸ GSK3B P49841 1/20 0.35
▸ PDGFRB P09619 2/20 0.34
▸ KDR P35968 2/20 0.34
▸ PIK3CA P42336 2/20 0.33
▸ FPR2 P25090 1/20 0.33
▸ FFAR1 O14842 1/20 0.33
▸ MTOR P42345 1/20 0.33
▸ CA1 P00915 1/20 0.33
▸ CA2 P00918 1/20 0.33
▸ CA9 Q16790 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29555798 1.00 ALPL (0.46) ALPLAAK1DGAT1LPLLIPG
SCHEMBL251502 0.89 ALPL (0.45) ALPLAAK1DGAT1LPLLIPG
SCHEMBL3515303 0.88 AAK1 (0.44) ALPLAAK1DGAT1LPLLIPG
SCHEMBL613434 0.88 AAK1 (0.46) ALPLAAK1DGAT1LPLLIPG
SCHEMBL3515180 0.87 AAK1 (0.43) ALPLAAK1DGAT1LPLLIPG
SCHEMBL23663237 0.86 ALPL (0.45) ALPLAAK1DGAT1LPLLIPG
SCHEMBL21823661 0.86 ALPL (0.41) ALPLAAK1DGAT1LPLLIPG
SCHEMBL20045356 0.86 ALPL (0.41) ALPLAAK1DGAT1LPLLIPG
SCHEMBL3515122 0.84 CSF1R (0.39) ALPLAAK1DGAT1LPLLIPG
SCHEMBL3668559 0.84 ALPL (0.46) ALPLAAK1DGAT1LPLLIPG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528822-B2 Cycloalkane-1,3-diamine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2026-01-20 — — US disclosed
US-20250197375-A1 PYRIMIDINES AND METHODS OF THEIR USE Kineta, Inc. 2025-06-19 — — US disclosed
EP-4444309-A1 PYRIMIDINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2024-10-16 — — EP disclosed
US-20240199654-A1 CTLA-4 SMALL MOLECULE DEGRADATION AGENT AND APPLICATION THEREOF SUZHOU GUOKUANG PHARMTECH. CO., LTD. (CN) 2024-06-20 — — US disclosed
US-11964962-B2 Substituted pyridazinone compound and use thereof Shandong First Medical University & Shandong Academy Of Medical Sciences (CN) 2024-04-23 — — US disclosed
EP-3892278-B1 CYCLOALKANE-1,3-DIAMINE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2024-02-28 — — EP disclosed
EP-3892278-B1 CYCLOALKANE-1,3-DIAMINE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2024-02-28 — — EP disclosed
EP-4310081-A1 CTLA-4 SMALL MOLECULE DEGRADATION AGENT AND APPLICATION THEREOF Suzhou Guokuang Pharmtech. Co., Ltd. (CN) 2024-01-24 — — EP disclosed
EP-4310081-A1 CTLA-4 SMALL MOLECULE DEGRADATION AGENT AND APPLICATION THEREOF Suzhou Guokuang Pharmtech. Co., Ltd. (CN) 2024-01-24 — — EP disclosed
CN-117157284-A CTLA-4 small molecule degradation agent and application thereof 苏州国匡医药科技有限公司 2023-12-01 — — CN disclosed
US-20120071474-A1 INHIBITORS OF PI3 KINASE AMGEN INC. (US) 2012-03-22 — — US disclosed
US-20120040950-A1 ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-16 — — US disclosed
US-20120040950-A1 ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-16 — — US disclosed
US-20120040950-A1 ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-16 — — US disclosed
EP-2408773-A2 INHIBITORS OF PI3 KINASE Amgen, Inc (US) 2012-01-25 — — EP disclosed
WO-2011087776-A1 ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-21 — — WO disclosed
WO-2011087776-A1 ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-21 — — WO disclosed
WO-2010108074-A2 INHIBITORS OF PI3 KINASE AMGEN INC. (US) 2010-09-23 — — WO disclosed
EP-2164840-A2 MODULATORS OF CFTR Vertex Pharmaceuticals Incorporated (US) 2010-03-24 — — EP disclosed
WO-2008141119-A2 MODULATORS OF CFTR VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071474-A1 INHIBITORS OF PI3 KINASE PIK3CA, PIK3CD, PIK3CG ALPL 2413/4885AAK1 502/4885DGAT1 2489/4885
US-20120040950-A1 ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE PIK3CD, PIK3CA, PIK3R5 ALPL 2676/4885AAK1 390/4885DGAT1 963/4885
US-11964962-B2 Substituted pyridazinone compound and use thereof THRB, TPO, TSHR ALPL 602/4885AAK1 2120/4885DGAT1 4406/4885
US-20250197375-A1 PYRIMIDINES AND METHODS OF THEIR USE TDP1, TYMP, TARDBP ALPL 3991/4885AAK1 2485/4885DGAT1 4259/4885
US-20240199654-A1 CTLA-4 SMALL MOLECULE DEGRADATION AGENT AND APPLICATION THEREOF CD274, PDCD1, PDCD1LG2 ALPL 1042/4885AAK1 3879/4885DGAT1 4006/4885
US-12528822-B2 Cycloalkane-1,3-diamine derivative MLLT1, MLLT3, PRMT6 ALPL 4852/4885AAK1 3644/4885DGAT1 3718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.